Use Of Pragmatic Clinical Trials To Support Drug Launch
OBJECTIVES: Pragmatic clinical trials (PCTs) are currently an important topic of interest in drug development. Increasing external validity of trials, PCTs have the potential to close the gap between internal validity of explanatory trials and real-life practice. The objective of this study was to a...
Saved in:
Published in | Value in health Vol. 20; no. 9; pp. A660 - A661 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Lawrenceville
Elsevier Science Ltd
01.10.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | OBJECTIVES: Pragmatic clinical trials (PCTs) are currently an important topic of interest in drug development. Increasing external validity of trials, PCTs have the potential to close the gap between internal validity of explanatory trials and real-life practice. The objective of this study was to assess the current use of PCTs to support drug launch. METHODS: Peer-reviewed articles on PCTs were searched in Medline/ Embase through Ovid. In addition, search of the EUnetHTA and EU Commission websites was performed, supplemented by Google search of grey literature. RESULTS: PCTs are currently on the rise; however, their use to support drug launch is uncommon. PCTs have several limitations, i.e., 1) methodological/analytical issues inherent to the potential risk of bias of more flexible designs, 2) operational issues with coordinating the recruitment of large patient populations from different settings, 3) concerns of regulatory and ethical nature, e.g. securing rights and interests of participants while remaining pragmatically flexible, 4) substantial costs incurred to conduct large PCTs. In the United States, PCTs are currently mainly promoted through public sector funding, while their potential use by regulators and payers is still uncertain. Before PCTs can be used for decision-making, academic experience (e.g. from the National Institutes of Health Health Care Systems Research Collaboratory, the National Patient-Centered Clinical Research Network, the Clinical Trials TYansformation Initiative) with these trials should broaden. In Europe, PCTs are usually considered by decision-makers as complementing (but not replacing) standard randomised clinical trials. Evidence from PCTs seems more acceptable for drugs with a known benefit/risk profiles, while less acceptable for drugs with novel mechanisms of action. CONCLUSIONS: PCTs are currently underused for initial drug regulatory/reimbursement dossier filing. Currently, multi-stakeholder initiatives are undertaken to enhance pragmatism in clinical trials and reduce decisionmaking uncertainty through developing tools, guidelines, and research on new trial designs and statistical methodologies. |
---|---|
AbstractList | OBJECTIVES: Pragmatic clinical trials (PCTs) are currently an important topic of interest in drug development. Increasing external validity of trials, PCTs have the potential to close the gap between internal validity of explanatory trials and real-life practice. The objective of this study was to assess the current use of PCTs to support drug launch. METHODS: Peer-reviewed articles on PCTs were searched in Medline/ Embase through Ovid. In addition, search of the EUnetHTA and EU Commission websites was performed, supplemented by Google search of grey literature. RESULTS: PCTs are currently on the rise; however, their use to support drug launch is uncommon. PCTs have several limitations, i.e., 1) methodological/analytical issues inherent to the potential risk of bias of more flexible designs, 2) operational issues with coordinating the recruitment of large patient populations from different settings, 3) concerns of regulatory and ethical nature, e.g. securing rights and interests of participants while remaining pragmatically flexible, 4) substantial costs incurred to conduct large PCTs. In the United States, PCTs are currently mainly promoted through public sector funding, while their potential use by regulators and payers is still uncertain. Before PCTs can be used for decision-making, academic experience (e.g. from the National Institutes of Health Health Care Systems Research Collaboratory, the National Patient-Centered Clinical Research Network, the Clinical Trials TYansformation Initiative) with these trials should broaden. In Europe, PCTs are usually considered by decision-makers as complementing (but not replacing) standard randomised clinical trials. Evidence from PCTs seems more acceptable for drugs with a known benefit/risk profiles, while less acceptable for drugs with novel mechanisms of action. CONCLUSIONS: PCTs are currently underused for initial drug regulatory/reimbursement dossier filing. Currently, multi-stakeholder initiatives are undertaken to enhance pragmatism in clinical trials and reduce decisionmaking uncertainty through developing tools, guidelines, and research on new trial designs and statistical methodologies. |
Author | Rémuzat, C Kloc, K Toumi, M |
Author_xml | – sequence: 1 givenname: C surname: Rémuzat fullname: Rémuzat, C – sequence: 2 givenname: K surname: Kloc fullname: Kloc, K – sequence: 3 givenname: M surname: Toumi fullname: Toumi, M |
BookMark | eNotkF1LwzAUhoMouE1_gTcBr1tz8t1LmZ8wmOB2HdI0mS1dW5NV8N_bMt-b88J5OAeeJbrs-s4jdAckBwLyocmbH9vmlIDKic5BaHGBFiAoz7hi7HLqpNAZIyCu0TKlhhAiGRULpPbJ423AH9EejvZUO7xu6652tsW7WNs24V2PP8dh6OMJP8XxgDd27NzXDboK09bf_s8V2r8879Zv2Wb7-r5-3GQOQImMSZChDJUWlDpBbKmCk0yUFYQpoiq4LSWnVHqvWaU8KZysKlYSrqkS3LMVuj_fHWL_Pfp0Mk0_xm56aSgAU1TKgk8UO1Mu9ilFH8wQ66ONvwaImQ2ZxsyGzGzIEG1mQ-wPEABa_Q |
ContentType | Journal Article |
Copyright | Copyright Elsevier Science Ltd. Oct/Nov 2017 |
Copyright_xml | – notice: Copyright Elsevier Science Ltd. Oct/Nov 2017 |
DBID | AAYXX CITATION 7QJ |
DOI | 10.1016/j.jval.2017.08.1585 |
DatabaseName | CrossRef Applied Social Sciences Index & Abstracts (ASSIA) |
DatabaseTitle | CrossRef Applied Social Sciences Index and Abstracts (ASSIA) |
DatabaseTitleList | Applied Social Sciences Index and Abstracts (ASSIA) |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1524-4733 |
EndPage | A661 |
ExternalDocumentID | 10_1016_j_jval_2017_08_1585 |
GeographicLocations | United States--US Europe |
GeographicLocations_xml | – name: Europe – name: United States--US |
GroupedDBID | --- --K --M .1- .3N .FO .GA .Y3 .~1 0R~ 0SF 10A 123 1OC 1P~ 1~. 29Q 31~ 36B 4.4 44B 457 4G. 51W 51X 52N 52P 52R 52S 52X 53G 5LA 5VS 66C 6I. 6PF 7-5 7PT 8-1 8P~ 8UM AACTN AAEDT AAEDW AAFJI AAFTH AAFWJ AAHHS AAIKJ AAKOC AALRI AAOAW AAPFB AAQFI AAQXK AAWTL AAXKI AAXUO AAYXX ABBQC ABCQN ABDBF ABEML ABIVO ABJNI ABMAC ABMMH ABMZM ABVKL ABXDB ACCFJ ACDAQ ACGFS ACHQT ACPRK ACRLP ACXQS ADBBV ADEZE ADFHU ADMUD ADVLN AEBSH AEEZP AEKER AENEX AEQDE AEVXI AEXQZ AEYQN AFBPY AFCTW AFEBI AFJKZ AFKWA AFRHN AFTJW AFXIZ AFZJQ AGHFR AGTHC AGUBO AGYEJ AIEXJ AIIAU AIKHN AITUG AIWBW AJAOE AJBDE AJOXV AJRQY AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AOMHK ASPBG AVARZ AVWKF AXJTR AXLSJ AZFZN BAWUL BFHJK BKOJK BLXMC BNPGV BY8 CAG CITATION CO8 COF CS3 DCZOG DIK DU5 EAD EAP EBS EFJIC EJD EMB EMK EMOBN ESX F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN GBLVA HF~ HVGLF HZI HZ~ IHE IXB KOM M41 MO0 N9A NCXOZ O-L O9- OAUVE OIG OK1 OVD P-8 P-9 P2P PC. PQQKQ PRBVW Q38 QB0 R2- RIG ROL SDF SEL SES SPCBC SSB SSF SSH SSO SSZ SUPJJ SV3 T5K TEORI TUS W99 WYUIH XG1 YFH Z5R ~G- 7QJ |
ID | FETCH-LOGICAL-c1175-3616fbfd8522c50ab7fc635bd1ffff5d94ab64226ee83d7e09c6dd3b0482754e3 |
ISSN | 1098-3015 |
IngestDate | Thu Oct 10 22:05:38 EDT 2024 Thu Sep 26 16:56:59 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c1175-3616fbfd8522c50ab7fc635bd1ffff5d94ab64226ee83d7e09c6dd3b0482754e3 |
OpenAccessLink | http://www.valueinhealthjournal.com/article/S1098301517319198/pdf |
PQID | 2113726694 |
PQPubID | 105593 |
ParticipantIDs | proquest_journals_2113726694 crossref_primary_10_1016_j_jval_2017_08_1585 |
PublicationCentury | 2000 |
PublicationDate | 2017-10-00 20171001 |
PublicationDateYYYYMMDD | 2017-10-01 |
PublicationDate_xml | – month: 10 year: 2017 text: 2017-10-00 |
PublicationDecade | 2010 |
PublicationPlace | Lawrenceville |
PublicationPlace_xml | – name: Lawrenceville |
PublicationTitle | Value in health |
PublicationYear | 2017 |
Publisher | Elsevier Science Ltd |
Publisher_xml | – name: Elsevier Science Ltd |
SSID | ssj0006325 |
Score | 2.219992 |
Snippet | OBJECTIVES: Pragmatic clinical trials (PCTs) are currently an important topic of interest in drug development. Increasing external validity of trials, PCTs... |
SourceID | proquest crossref |
SourceType | Aggregation Database |
StartPage | A660 |
SubjectTerms | Bias Clinical research Clinical trials Decision makers Decision making Drug development Health care expenditures Internal validity Patient-centered care Pragmatism Public sector R&D Recruitment Research & development Uncertainty Websites |
Title | Use Of Pragmatic Clinical Trials To Support Drug Launch |
URI | https://www.proquest.com/docview/2113726694 |
Volume | 20 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9tAEF61IKFeKppSkQLVHlAuiSO_1ps9ImgVgWg4OBU3a19GRCWpSHyAA7-dWe_ajgGhgg8rx4dJst_szux45huEDlXEuS8U8WIuzEBCjymqPMaUCGUcJUKYeMf572Q8jU8vyWXTma6sLlmJobx_sa7kPajCM8DVVMm-AdlaKDyAe8AXRkAYxv_CeLrU_UnJOXRlmVePqzrHtPz2frrom7ad4GL3T26LK1MFPXehK-eQ_uF_i5I3xBZE1u9f7Av0m-Ker1qx1DMwfq3oaLoobq6bsKoLIIBRqlLRqj3PUIrCOifrm2Lor4HP1na4o8Ty_ztrCR-DF3diGxSYDWcwrSaDjhqm1IDY_jxt3usn9qjOEqwS0GaZEZIZIZk_yoyQj2gzpIyYHM7hQ5PTk0Rll936H1U0U2VC37Nf0nZF2pa4dC_SbfTZnQvwkQX5C_qg5x20de4yHzqod2E5xu8GOG1K5pYD3MMXDfv43VdEQSnwJMe1UuBKKbBVCpwusFMKbJQCW6XYQdNfP9Pjsee6Y3jS0Kt6URIkucjVCDxoSXwuaC7BexQqyOEiisHqS0ydtNajSFHtM5koFQnfEL-SWEff0MZ8Mde7CEsqfV-znMeBjoWkTEpNeB7QEYfzeE66aFBNVPbPkqBkr4DTRfvVZGZutSyzMAgiCt4gi7-_Tdoe-tRo7T7aWN0W-gAcwZX4UYL_CIFDWVI |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Elsevier |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Use+Of+Pragmatic+Clinical+Trials+To+Support+Drug+Launch&rft.jtitle=Value+in+health&rft.au=R%C3%A9muzat%2C+C&rft.au=Kloc%2C+K&rft.au=Toumi%2C+M&rft.date=2017-10-01&rft.issn=1098-3015&rft.volume=20&rft.issue=9&rft.spage=A660&rft.epage=A661&rft_id=info:doi/10.1016%2Fj.jval.2017.08.1585&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_jval_2017_08_1585 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1098-3015&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1098-3015&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1098-3015&client=summon |